Takeda Moves Incontinence Candidate To New Venture
This article was originally published in PharmAsia News
Takeda has licensed a non-core pipeline asset in the urology field to a new venture co-founded by its former top R&D executive.
You may also be interested in...
Takeda Takes Alliance Route For Norovirus Vaccine
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.
Tech Transfer Roundup: MD Anderson, Replay Found Allogeneic TCR-NK Cell Therapy Play Syena
Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.